Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We believe human-derived knowledge will better predict which antibody drug candidates are most likely to be effective in a targeted group of patients, with the goals of reducing side effects and accelerating the drug discovery and development process.
We study rare immune cells from human patients at high resolution and measure drug effects in a patient-specific, disease-specific manner. Harnessing The Power of Human™, our platform provides a basis for developing best-in-class product candidates from a fundamental understanding of how immunotherapies work in each patient.
November 18, 2015
Enumeral Reports That Its Novel Class of Potentially Allosteric Anti-PD-1 Antibodies Can Elicit an Additive Effect on T Cell Activation in Ex Vivo Human Assays When Used in Combination With A Currently Marketed Anti-PD-1 Antibody
November 10, 2015